相关实验视频

Updated: May 22, 2025

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

针对慢性淋巴细胞白血病中的瘤微环境相互作用,使用白血抑制剂

Laia Sadeghi¹, Magali Merrien², Magnus Björkholm³

¹Department of Laboratory Medicine, Division of Biomolecular and Cellular Medicine, Karolinska Institutet, 17177 Stockholm, Sweden.

International journal of molecular sciences

|March 13, 2025

概括

抑制5-氧酶 (5-LOX) 途径降低了慢性淋巴细胞白血病 (CLL) 细胞对支持性树皮细胞的粘附. 这表明5-LOX抑制剂是CLL患者潜在的新疗法.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

慢性淋巴细胞白血病 (CLL) 细胞生存和增殖取决于瘤微环境中的相互作用.
B细胞受体 (BCR) 信号传递,由瘤细胞粘附于树皮细胞激活,对CLL细胞存活至关重要.
目前布鲁顿的氨酸激酶抑制剂 (BTKi) 是有效的,但面临的挑战是耐药性和毒性.

研究的目的:

调查5-利氧基酶 (5-LOX) 途径抑制剂作为CLL的新治疗策略的潜力.
为了评估5-LOX抑制对CLL细胞粘附于脑膜细胞的作用,在一个ex vivo模型中.
为了比较5-LOX抑制剂与ibrutinib在降低CLL细胞粘附方面的疗效.

主要方法:

使用了ex vivo共同培养模型来评估CLL细胞对树皮细胞的粘附.
经过测试的5-LOX路径抑制剂 (zileuton,MK886) 和BTKi的ibrutinib.
在各种CLL患者样本中分析了差异性粘附模式.

主要成果:

在患者样本中,CLL细胞对树皮细胞的粘附有显著差异.
抑制5-LOX通路导致CLL细胞粘附的变量减少.
对5-LOX抑制剂的反应谱与ibrutinib的反应谱不同.
确定了临床/遗传特征和CLL细胞粘附之间的相关性.

结论:

5-脂氧酶 (5-LOX) 途径是慢性淋巴细胞白血病 (CLL) 的潜在治疗标.
5-LOX抑制剂在减少CLL细胞对微环境的粘附方面表现出活性.
对5-LOX路径抑制剂的进一步研究对于CLL治疗的发展是有必要的.

关键词:

在5-LOX路径中.BTKiKi 的意思是在MK886中,MK886是慢性淋巴细胞白血病慢性淋巴细胞白血病共同文化是一种共同文化.瘤微环境是一个微环境.这里是Zileuton,Zileuton就是Zileuton.

更多相关视频

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.